F.T.C. Settles With Express Scripts Over High Insulin Prices

The Federal Trade Commission said it had reached a settlement with Cigna’s Express Scripts over its role in driving up insulin prices. Express Scripts will not pay a fine or admit wrongdoing but agreed to a range of changes to its business model. Under the settlement, the company agreed to measures intended to lower out-of-pocket costs for patients and reduce spending for employers and government programs.

Express Scripts also agreed to move a Swiss subsidiary back to the United States to handle price negotiations, a change critics said would improve transparency and tax treatment. The F.T.C. has continued action against CVS Health’s Caremark and UnitedHealth’s Optum Rx; the agency sued the three pharmacy benefit managers in 2024, accusing them of inflating insulin prices and steering patients toward higher-cost products.

The three firms together control about 80 percent of the PBM market.

federal trade commission, express scripts, cigna, insulin prices, ftc settlement, swiss subsidiary, united states, caremark, optum rx, pharmacy benefit managers